Neurogene (NGNE) Stock Price, News & Analysis

Company Overview

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Key Stats

• Today's Range: $9.37 to $10.54
• 50-Day Range: $9.65 to $23.30
• 52-Week Range: $9.22 to $74.49
• Volume: 225,967 shs
• Average Volume: 214,093 shs
• Market Capitalization: $144.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $59.80
• Consensus Rating: Buy

Neurogene Stock Analysis - MarketRank™

Neurogene scored higher than 48% of companies evaluated by MarketBeat, and ranked 545th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Neurogene has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Neurogene has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neurogene are expected to grow in the coming year, from ($4.27) to ($4.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neurogene is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neurogene is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neurogene has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

12.59% of the float of Neurogene has been sold short.

Short Interest Ratio / Days to Cover

Neurogene has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in Neurogene has recently increased by 11.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neurogene does not currently pay a dividend.

Dividend Growth

Neurogene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

12.59% of the float of Neurogene has been sold short.

Short Interest Ratio / Days to Cover

Neurogene has a short interest ratio ("days to cover") of 9.3.

Change versus previous month

Short interest in Neurogene has recently increased by 11.22%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.80

News Sentiment

Neurogene has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Neurogene this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 1 people have added Neurogene to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neurogene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,247.00 in company stock.

Percentage Held by Insiders

Only 9.92% of the stock of Neurogene is held by insiders.

Percentage Held by Institutions

52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NGNE Stock Analysis - Frequently Asked Questions

How have NGNE shares performed this year?

Neurogene's stock was trading at $22.86 on January 1st, 2025. Since then, NGNE shares have decreased by 57.7% and is now trading at $9.67.
View the best growth stocks for 2025 here.

How were Neurogene's earnings last quarter?

Neurogene Inc. (NASDAQ:NGNE) released its quarterly earnings data on Monday, March, 24th. The company reported ($0.99) EPS for the quarter, topping the consensus estimate of ($1.04) by $0.05. The business earned $0.93 million during the quarter.

How do I buy shares of Neurogene?

Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Neurogene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 3/24/2025
• Today: 4/03/2025
• Next Earnings (Estimated): 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NGNE
• Previous Symbol: NASDAQ:NGNE
• CIK: 1404644
• Web: www.neurogene.com
• Phone: (877) 237-5020
• Fax: 778-331-4486
• Employees: 90
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $59.80
• High Stock Price Target: $72.00
• Low Stock Price Target: $45.00
• Potential Upside/Downside: +488.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.13
• Research Coverage: 8 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-36,320,000.00
• Net Margins: N/A
• Pretax Margin: -5,756.43%
• Return on Equity: -32.81%
• Return on Assets: -27.96%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.09
• Quick Ratio: 9.09

Sales & Book Value

• Annual Sales: $925,000.00
• Price / Sales: 163.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.51 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 14,930,000
• Free Float: 13,381,000
• Market Cap: $151.69 million
• Optionable: Optionable
• Beta: 1.01